EA201591072A1 - Антитела против pdgfr-бета и их применения - Google Patents

Антитела против pdgfr-бета и их применения

Info

Publication number
EA201591072A1
EA201591072A1 EA201591072A EA201591072A EA201591072A1 EA 201591072 A1 EA201591072 A1 EA 201591072A1 EA 201591072 A EA201591072 A EA 201591072A EA 201591072 A EA201591072 A EA 201591072A EA 201591072 A1 EA201591072 A1 EA 201591072A1
Authority
EA
Eurasian Patent Office
Prior art keywords
beta
pdgfr
antibodies
diseases
applications
Prior art date
Application number
EA201591072A
Other languages
English (en)
Other versions
EA031049B1 (ru
Inventor
Стэнли Дж. Уиганд
Иван Б. Лобов
Original Assignee
Ридженерон Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ридженерон Фармасьютикалз, Инк. filed Critical Ридженерон Фармасьютикалз, Инк.
Publication of EA201591072A1 publication Critical patent/EA201591072A1/ru
Publication of EA031049B1 publication Critical patent/EA031049B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Reproductive Health (AREA)
  • Pulmonology (AREA)

Abstract

Изобретение относится к антителам, которые связываются с рецептором бета полученного из тромбоцитов фактора роста (PDGFR-бета), и к способам их применения. Согласно некоторым вариантам осуществления изобретения антитела представляют собой полностью человеческие антитела, которые связываются в PDGFR-бета человека с высокой аффинностью. Антитела по изобретению применимы для лечения заболеваний и расстройств, ассоциированных с передачей сигнала PDGFR-бета и/или клеточной экспрессией PDGFR-бета, таких как глазные болезни, фиброзные болезни, сосудистые заболевания и злокачественные опухоли.
EA201591072A 2013-01-09 2014-01-07 Антитела против pdgfr-бета и их применения EA031049B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361750437P 2013-01-09 2013-01-09
US201361863452P 2013-08-08 2013-08-08
US201361909421P 2013-11-27 2013-11-27
PCT/US2014/010395 WO2014109999A1 (en) 2013-01-09 2014-01-07 ANTI-PDGFR-beta ANTIBODIES AND USES THEREOF

Publications (2)

Publication Number Publication Date
EA201591072A1 true EA201591072A1 (ru) 2015-12-30
EA031049B1 EA031049B1 (ru) 2018-11-30

Family

ID=50002880

Family Applications (2)

Application Number Title Priority Date Filing Date
EA201890143A EA201890143A3 (ru) 2013-01-09 2014-01-07 Антитела против pdgfr-бета и их применения
EA201591072A EA031049B1 (ru) 2013-01-09 2014-01-07 Антитела против pdgfr-бета и их применения

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EA201890143A EA201890143A3 (ru) 2013-01-09 2014-01-07 Антитела против pdgfr-бета и их применения

Country Status (22)

Country Link
US (3) US9265827B2 (ru)
EP (1) EP2943218B1 (ru)
JP (1) JP6367233B2 (ru)
KR (1) KR102146692B1 (ru)
CN (1) CN104936614B (ru)
AU (3) AU2014205641B2 (ru)
BR (1) BR112015016312B1 (ru)
CA (1) CA2897383C (ru)
CL (2) CL2015001924A1 (ru)
EA (2) EA201890143A3 (ru)
HK (1) HK1214969A1 (ru)
IL (2) IL239552B (ru)
JO (1) JO3405B1 (ru)
MX (1) MX363635B (ru)
MY (1) MY169165A (ru)
NZ (1) NZ709683A (ru)
PH (1) PH12015501493B1 (ru)
SG (2) SG10201701308VA (ru)
TW (1) TWI647239B (ru)
UY (1) UY35258A (ru)
WO (1) WO2014109999A1 (ru)
ZA (1) ZA201504537B (ru)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
AR095196A1 (es) 2013-03-15 2015-09-30 Regeneron Pharma Medio de cultivo celular libre de suero
MX2016000364A (es) 2013-07-12 2016-05-09 Ophthotech Corp Metodos para tratar o prevenir afecciones oftalmologicas.
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
KR102399028B1 (ko) 2014-03-21 2022-05-17 엑스-바디 인코포레이티드 이중-특이적 항원-결합 폴리펩티드
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
MX2017005642A (es) 2014-11-10 2017-07-24 Hoffmann La Roche Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso.
CA2963719A1 (en) 2014-11-10 2016-05-19 F. Hoffmann-La Roche Ag Anti-il-1beta antibodies and methods of use
KR20170080584A (ko) 2014-11-10 2017-07-10 에프. 호프만-라 로슈 아게 이중특이적 항체 및 안과학에서 이의 사용 방법
CN107148429B (zh) * 2014-11-10 2021-12-03 豪夫迈·罗氏有限公司 抗-pdgf-b抗体和使用方法
US20160144025A1 (en) * 2014-11-25 2016-05-26 Regeneron Pharmaceuticals, Inc. Methods and formulations for treating vascular eye diseases
JP2018506280A (ja) * 2015-02-06 2018-03-08 カドモン コーポレイション，リミティド ライアビリティ カンパニー 免疫調節薬
EP3973977A1 (en) * 2015-03-31 2022-03-30 Ildong Pharm Co., Ltd. Pharmaceutical composition for preventing and treating eye diseases, containing, as active ingredient, fusion protein in which tissue-penetrating peptide and anti-vascular endothelial growth factor preparation are fused
AU2016298398A1 (en) 2015-07-29 2018-02-08 Allergan, Inc. Heavy chain only antibodies to ANG-2
TWI797060B (zh) 2015-08-04 2023-04-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
IL302211A (en) 2015-12-16 2023-06-01 Regeneron Pharma Preparations and methods for making protein microparticles
WO2017117464A1 (en) 2015-12-30 2017-07-06 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2018005904A2 (en) * 2016-07-01 2018-01-04 Ludwig Institute For Cancer Research Ltd Methods and compositions for pdgf-cc inhibition
EA201990317A1 (ru) 2016-08-16 2019-07-31 Ридженерон Фармасьютикалз, Инк. Способы определения количества индивидуальных антител из смеси
EP3504328A1 (en) 2016-08-24 2019-07-03 Regeneron Pharmaceuticals, Inc. Host cell protein modification
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
CN109021104B (zh) * 2017-06-12 2022-08-12 上海睿智化学研究有限公司 一种抗人血小板衍生生长因子β受体的抗体及其应用
KR20210084695A (ko) 2017-07-06 2021-07-07 리제너론 파마슈티칼스 인코포레이티드 당단백질을 만들기 위한 세포 배양 과정
CA3084059A1 (en) 2017-12-22 2019-06-27 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
US20190234959A1 (en) 2018-01-31 2019-08-01 Regeneron Pharmaceuticals, Inc. System and method for characterizing drug product impurities
TW202311746A (zh) 2018-02-02 2023-03-16 美商再生元醫藥公司 用於表徵蛋白質二聚合之系統及方法
US20190264293A1 (en) 2018-02-28 2019-08-29 Regeneron Pharmaceuticals, Inc. Systems and methods for identifying viral contaminants
BR112020015291B1 (pt) 2018-03-19 2023-09-26 Regeneron Pharmaceuticals, Inc Tampão de amostra de eletroforese aquoso, método para identificar contaminantes ou impurezas em uma amostra de fármaco proteico, e, kit
GB201806918D0 (en) * 2018-04-27 2018-06-13 Enleofen Bio Pte Ltd Combination treatment for eye fibrosis
CN108586611B (zh) * 2018-04-28 2021-01-26 暨南大学 重组全人源抗破伤风毒素单克隆抗体
TW202016125A (zh) 2018-05-10 2020-05-01 美商再生元醫藥公司 用於定量及調節蛋白質黏度之系統與方法
EP3774841A1 (en) 2018-08-27 2021-02-17 Regeneron Pharmaceuticals, Inc. Use of raman spectroscopy in downstream purification
BR112020026348A2 (pt) 2018-08-30 2021-03-30 Regeneron Pharmaceuticals, Inc. Método para avaliar a estequiometria e distribuição de tamanho de complexos de proteínas, para selecionar um medicamento de proteína principal e para caracterizar complexos de proteínas, e, composição farmacêutica
CN113166249A (zh) * 2018-10-05 2021-07-23 首尔大学校产学协力团 Pdgf受体抗体及其用途
WO2020150492A1 (en) 2019-01-16 2020-07-23 Regeneron Pharmaceuticals, Inc. Methods for identifying free thiols in proteins
WO2020185069A1 (en) * 2019-03-08 2020-09-17 Linxis B.V. Internalizing binding molecules targeting receptors involved in cell proliferation or cell differentiation
US11813311B2 (en) 2019-05-03 2023-11-14 Singapore Health Services Pte Ltd. Treatment and prevention of metabolic diseases
EP3969908A1 (en) 2019-05-13 2022-03-23 Regeneron Pharmaceuticals, Inc. Improved competitive ligand binding assays
JP2022548394A (ja) 2019-09-24 2022-11-18 リジェネロン・ファーマシューティカルズ・インコーポレイテッド クロマトグラフィーの使用および再生のためのシステムおよび方法
CA3157509A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
JP2023502500A (ja) 2019-11-25 2023-01-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 非水性エマルションを使用した持続放出製剤
WO2021142086A1 (en) 2020-01-08 2021-07-15 Synthis Therapeutics, Inc. Alk5 inhibitor conjugates and uses thereof
IL294765B2 (en) 2020-01-21 2023-12-01 Regeneron Pharma Deglycosylation methods for electrophoresis of glycosylated proteins
AU2021332355A1 (en) 2020-08-31 2023-03-23 Regeneron Pharmaceuticals, Inc. Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants
EP4214235A1 (en) * 2020-09-16 2023-07-26 LinXis B.V. Internalizing binding molecules
WO2022115588A1 (en) 2020-11-25 2022-06-02 Regeneron Pharmaceuticals, Inc. Sustained release formulations using non-aqueous membrane emulsification
AU2021401301A1 (en) 2020-12-17 2023-08-03 Regeneron Pharmaceuticals, Inc. Fabrication of protein-encapsulating microgels
TW202233827A (zh) 2021-01-20 2022-09-01 美商再生元醫藥公司 改良細胞培養中蛋白質效價的方法
US20220404369A1 (en) 2021-03-03 2022-12-22 Regeneron Pharmaceuticals, Inc. Systems and methods for quantifying and modifying protein viscosity
IL305731A (en) 2021-03-26 2023-11-01 Regeneron Pharma Methods and systems for developing mixing protocols
WO2022256383A1 (en) 2021-06-01 2022-12-08 Regeneron Pharmaceuticals, Inc. Micropchip capillary electrophoresis assays and reagents
AR127006A1 (es) 2021-09-08 2023-12-06 Regeneron Pharma UN MÉTODO BASADO EN ESPECTROMETRÍA DE MASAS Y DE ALTO RENDIMIENTO PARA CUANTIFICAR ANTICUERPOS Y OTRAS PROTEÍNAS QUE CONTIENEN Fc
CA3232463A1 (en) 2021-09-20 2023-03-23 Philip Mellors Methods of controlling antibody heterogeneity
CA3230984A1 (en) 2021-10-07 2023-04-13 Ross BROWNE Systems and methods of ph modeling and control
IL311248A (en) 2021-10-07 2024-05-01 Regeneron Pharma PH meter calibration and repair
US20230129265A1 (en) 2021-10-26 2023-04-27 Regeneron Pharmaceuticals, Inc. Systems and methods for generating laboratory water and distributing laboratory water at different temperatures
TW202346856A (zh) 2022-03-18 2023-12-01 美商里珍納龍藥品有限公司 分析多肽變體的方法及系統
US11723955B1 (en) 2022-05-13 2023-08-15 Allgenesis Biotherapeutics Inc. VEGFR fusion protein pharmaceutical composition

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE69231128T2 (de) 1991-01-31 2001-02-15 Univ California Domänen von extrazellulären bereichen von menschlichen blutplättchen abstammenden wachstumsfaktor rezeptor-polypeptiden
DE69233254T2 (de) 1991-06-14 2004-09-16 Genentech, Inc., South San Francisco Humanisierter Heregulin Antikörper
US20020009443A1 (en) * 1991-12-02 2002-01-24 Vanitha Ramakrishman Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
RU2194760C2 (ru) 1991-12-02 2002-12-20 Кор Терапьютикс, Инк. Иммуноглобулиновый полипептид, его фрагмент, композиция, штамм гибридных культивируемых клеток, способ получения полипептида
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5620687A (en) 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US7087411B2 (en) 1999-06-08 2006-08-08 Regeneron Pharmaceuticals, Inc. Fusion protein capable of binding VEGF
CN1934255B (zh) 2003-08-27 2012-07-11 奥普索特克公司 用于治疗眼新血管疾病的组合治疗
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
CA2652976C (en) 2006-06-02 2015-08-11 Regeneron Pharmaceuticals, Inc. High affinity antibodies to human il-6 receptor
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EA019595B1 (ru) * 2007-04-17 2014-04-30 Имклоун Элэлси СПЕЦИФИЧНЫЕ ИНГИБИТОРЫ PDGFRβ
WO2008153926A2 (en) 2007-06-05 2008-12-18 Yale University Inhibitors of receptor tyrosine kinases and methods of use thereof
CA2697077C (en) 2007-08-22 2012-10-16 Irm Llc 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
JP5425180B2 (ja) * 2008-03-27 2014-02-26 ザイモジェネティクス， インコーポレイテッド ＰＤＧＦＲβおよびＶＥＧＦ−Ａを阻害するための組成物および方法
EP2432476A4 (en) 2009-05-01 2013-03-20 Ophthotech Corp METHOD FOR THE TREATMENT OR PREVENTION OF EYE DISEASES
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
KR20220097542A (ko) 2011-01-13 2022-07-07 리제너론 파아마슈티컬스, 인크. 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
CN102250249A (zh) 2011-06-18 2011-11-23 常州亚当生物技术有限公司 一种抗VEGF/PDGFRbeta双特异性抗体及其应用

Also Published As

Publication number Publication date
MX363635B (es) 2019-03-29
ZA201504537B (en) 2016-07-27
EA031049B1 (ru) 2018-11-30
AU2017245479A1 (en) 2017-11-02
AU2018202814A1 (en) 2018-05-10
IL239552A0 (en) 2015-08-31
KR102146692B1 (ko) 2020-08-21
BR112015016312B1 (pt) 2020-12-15
KR20150103682A (ko) 2015-09-11
JO3405B1 (ar) 2019-10-20
HK1214969A1 (zh) 2016-08-12
US20140193402A1 (en) 2014-07-10
UY35258A (es) 2014-08-29
MY169165A (en) 2019-02-20
JP2016504416A (ja) 2016-02-12
CN104936614B (zh) 2018-09-18
IL245040B (en) 2020-05-31
US9650444B2 (en) 2017-05-16
SG10201701308VA (en) 2017-03-30
AU2018202814B2 (en) 2019-04-18
AU2017245479B2 (en) 2018-01-25
AU2017245479C1 (en) 2018-08-16
US20170210813A1 (en) 2017-07-27
TWI647239B (zh) 2019-01-11
CL2015001924A1 (es) 2016-06-10
EP2943218B1 (en) 2018-08-08
PH12015501493A1 (en) 2015-09-28
EA201890143A3 (ru) 2018-09-28
EP2943218A1 (en) 2015-11-18
AU2018202814B9 (en) 2019-06-06
IL245040A0 (en) 2016-05-31
CA2897383C (en) 2021-07-06
US9265827B2 (en) 2016-02-23
SG11201505035YA (en) 2015-07-30
CA2897383A1 (en) 2014-07-17
TW201441261A (zh) 2014-11-01
AU2014205641B2 (en) 2017-08-24
PH12015501493B1 (en) 2015-09-28
CN104936614A (zh) 2015-09-23
WO2014109999A1 (en) 2014-07-17
US10023642B2 (en) 2018-07-17
AU2014205641A1 (en) 2015-07-23
NZ709683A (en) 2019-01-25
IL239552B (en) 2019-01-31
MX2015008689A (es) 2015-10-05
CL2018000703A1 (es) 2018-07-06
EA201890143A2 (ru) 2018-05-31
US20160122433A1 (en) 2016-05-05
JP6367233B2 (ja) 2018-08-01

Similar Documents

Publication Publication Date Title
EA201591072A1 (ru) Антитела против pdgfr-бета и их применения
CY1123163T1 (el) Αντισωματα που δεσμευουν beta klotho επικρατεια 2 και μεθοδοι χρησης αυτων
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
PH12017500402A1 (en) Anti-glucagon antibodies and uses thereof
EA201892294A1 (ru) Антитела и композиции против tim-3
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
EA201890145A1 (ru) Антитела к фактору xi и способы их применения
PH12015501656A1 (en) Anti-il-33 antibodies and use thereof
EA201890131A1 (ru) Иммуномодуляция и лечение солидных опухолей антителами, которые специфически связывают cd38
EA201691824A1 (ru) АНТИТЕЛА ПРОТИВ EGFRvIII И ИХ ПРИМЕНЕНИЯ
EA201891732A1 (ru) Биспецифичные связывающие белки для pd-l1 и kdr
PH12016500943A1 (en) Aplnr modulatros and uses thereof
MX2015016111A (es) Anticuerpos anti-b7-h5 y sus usos.
EA201590402A1 (ru) ЧЕЛОВЕЧЕСКИЕ АНТИТЕЛА ПРОТИВ GFRα3 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
EA201591113A1 (ru) Антитела против антигена 2 дендритных клеток крови и их применение
MY180157A (en) Antibody formulations and uses thereof
EA201892440A1 (ru) Антитела к tl1a и их применения
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
EA201990978A1 (ru) Антитела против pd-1
MX2015015232A (es) Anticuerpo monoclonal dirigido contra cxcr5.
EA201792460A1 (ru) Связывающие tigit агенты и варианты их применения
EA202090128A2 (ru) Антитела против антигена 2 дендритных клеток крови и их применение